Sydney skin cancer patients join the EPIC-Skin study as they undergo first treatments with OncoBeta's Rhenium-SCT

/PRNewswire/ -- OncoBeta® GmbH has announced its first Sydney-based patients were treated with Rhenium-SCT® as part of the global phase IV EPIC-Skin Study...

Related Keywords

Germany ,New York ,United States ,Australia ,Munich ,Bayern ,Sydney ,New South Wales ,United Kingdom ,Ghana ,Garching ,Austria ,Gold Coast ,Ken Rikard Bell ,Sam Vohra ,Shannond Brown ,Oncobeta Gmb ,Prnewswire Oncobeta ,Therapeutic Nuclear Medicine ,Instagram ,Linkedin ,Facebook ,Skin Study ,Personalised Irradiation ,Medical Director ,Oncobeta Australia ,Patient Reported Outcomes ,Clinical Study ,Beta Australia Country Manager Ken Rikard Bell ,Managing Director ,Skin Cancer Therapy ,Basal Cell Carcinomas ,Squamous Cell Carcinomas ,Disease Cancer Collaboration ,Radionuclide Therapy ,Squamous Cell ,Risk Factors ,Oncobeta Gmbh ,